A trial flop for eFFECTOR Therapeutics (Nasdaq: EFTR) has prompted the Californian firm to drop development of its lead candidate, tomivosertib, in lung cancer.
The company, which focuses on selective translation regulator inhibitors, plans to carry on with a trial testing the candidate in acute myeloid leukemia (AML).
Announcing top-line results from the Phase II KICKSTART trial, the firm said median progression-free survival (PFS) was 13 weeks, compared with 11.7 weeks for the placebo arm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze